Kelderman Kim's Insider Trades & SAST Disclosures
Kelderman Kim's most recent trade in Bio-Techne Corp was a trade of 13,392 Common Stock done at an average price of $37.7 . Disclosure was reported to the exchange on Jan. 27, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Kelderman Kim.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Bio-Techne Corp | Kim Kelderman | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 37.70 per share. | 27 Jan 2025 | 13,392 | 52,396 (0%) | 0% | 37.7 | 504,878 | Common Stock |
| Bio-Techne Corp | Kim Kelderman | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jan 2025 | 13,392 | 0 | - | - | Stock Option (Right to Buy) | |
| Bio-Techne Corp | Kim Kelderman | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 77.19 per share. | 27 Jan 2025 | 11,731 | 40,665 (0%) | 0% | 77.2 | 905,533 | Common Stock |
| Bio-Techne Corp | Kim Kelderman | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 77.95 per share. | 27 Jan 2025 | 1,661 | 39,004 (0%) | 0% | 78.0 | 129,480 | Common Stock |
| Bio-Techne Corp | Kim Kelderman | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 75.31 per share. | 01 Nov 2024 | 2,430 | 39,004 (0%) | 0% | 75.3 | 183,003 | Common Stock |
| Bio-Techne Corp | Kim Kelderman | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 66.97 per share. | 29 Aug 2024 | 1,492 | 41,434 (0%) | 0% | 67.0 | 99,919 | Common Stock |
| Bio-Techne Corp | Kim Kelderman | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Aug 2024 | 1,492 | 115,724 | - | - | Stock Option (Right to Buy) | |
| Bio-Techne Corp | Kim Kelderman | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2024 | 69,061 | 69,061 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne Corp | Kim Kelderman | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2024 | 51,261 | 51,261 | - | - | Performance Restricted Stock Units | |
| Bio-Techne Corp | Kim Kelderman | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2024 | 25,630 | 25,630 | - | - | Restricted Stock Units | |
| Bio-Techne Corp | Kim Kelderman | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 37.70 per share. | 31 Jul 2024 | 14,000 | 49,421 (0%) | 0% | 37.7 | 527,800 | Common Stock |
| Bio-Techne Corp | Kim Kelderman | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jul 2024 | 14,000 | 13,392 | - | - | Stock Option (Right to Buy) | |
| Bio-Techne Corp | Kim Kelderman | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 81.97 per share. | 31 Jul 2024 | 9,479 | 39,942 (0%) | 0% | 82.0 | 776,994 | Common Stock |
| Bio-Techne Corp | Kelderman Kim | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2023 | 51,890 | 51,890 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne Corp | Kim Kelderman | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2023 | 25,945 | 25,945 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne Corp | Kim Kelderman | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2023 | 9,423 | 9,423 | - | - | Restricted Stock Units | |
| Bio-Techne Corp | Kim Kelderman | Pres. Diagnostics & Genom | Exercise or conversion of derivative security received from the company (such as an option) at price $ 47.60 per share. | 24 Aug 2023 | 2,100 | 21,225 (0%) | 0% | 47.6 | 99,960 | Common Stock |
| Bio-Techne Corp | Kim Kelderman | Pres. Diagnostics & Genom | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Aug 2023 | 2,100 | 109,536 | - | - | Stock Option (Right to Buy) | |
| Bio-Techne Corp | Kim Kelderman | Pres. Diagnostics & Genom | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2023 | 29,391 | 29,391 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne Corp | Kelderman Kim | Pres. Diagnostics & Genom | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2023 | 23,881 | 23,881 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne Corp | Kim Kelderman | Pres. Diagnostics & Genom | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2023 | 22,043 | 22,043 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne Corp | Kelderman Kim | Pres. Diagnostics & Genom | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2023 | 8,873 | 8,873 | - | - | Restricted Stock Units | |
| Bio-Techne Corp | Kim Kelderman | Pres. Diagnostics & Genom | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2023 | 8,191 | 8,191 | - | - | Restricted Stock Units | |
| Bio-Techne Corp | Kim Kelderman | Pres. Diagnostics & Genom | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2023 | 8,060 | 0 | - | - | Restricted Stock Units | |
| Bio-Techne Corp | Kim Kelderman | Pres. Diagnostics & Genom | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2023 | 8,060 | 23,264 (0%) | 0% | 0 | Common Stock | |
| Bio-Techne Corp | Kim Kelderman | Pres. Diagnostics & Genom | Payment of exercise price or tax liability using portion of securities received from the company at price $ 82.17 per share. | 05 Aug 2023 | 4,139 | 19,125 (0%) | 0% | 82.2 | 340,102 | Common Stock |
| Bio-Techne Corp | Kim Kelderman | Pres. Diagnostics & Genom | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Aug 2022 | 663 | 6,848 | - | - | Stock Option (Right to Buy) | |
| Bio-Techne Corp | Kim Kelderman | Pres. Diagnostics & Genom | Exercise or conversion of derivative security received from the company (such as an option) at price $ 150.78 per share. | 23 Aug 2022 | 663 | 3,801 (0%) | 0% | 150.8 | 99,967 | Common Stock |
| Bio-Techne Corp | Kim Kelderman | PRES. DIAGNOSTICS & GENOM | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2022 | 7,235 | 7,235 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne Corp | Kim Kelderman | PRES. DIAGNOSTICS & GENOM | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2022 | 5,426 | 5,426 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne Corp | Kim Kelderman | PRES. DIAGNOSTICS & GENOM | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2022 | 1,746 | 1,746 | - | - | Restricted Stock Units | |
| Bio-Techne Corp | Kim Kelderman | Pres. Diagnostics & Genom | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Aug 2022 | 2,363 | 0 | - | - | Restricted Stock Units | |
| Bio-Techne Corp | Kim Kelderman | Pres. Diagnostics & Genom | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Aug 2022 | 2,363 | 4,352 (0%) | 0% | 0 | Common Stock | |
| Bio-Techne Corp | Kim Kelderman | Pres. Diagnostics & Genom | Payment of exercise price or tax liability using portion of securities received from the company at price $ 382.97 per share. | 07 Aug 2022 | 1,214 | 3,138 (0%) | 0% | 383.0 | 464,926 | Common Stock |
| Bio-Techne Corp | Kim Kelderman | Pres. Diagnostics & Genom | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2022 | 1,989 | 7,511 | - | - | Stock Option (Right to Buy) | |
| Bio-Techne Corp | Kim Kelderman | Pres. Diagnostics & Genom | Exercise or conversion of derivative security received from the company (such as an option) at price $ 150.78 per share. | 08 Feb 2022 | 1,989 | 1,989 (0%) | 0% | 150.8 | 299,901 | Common Stock |
| Bio-Techne Corp | Kim Kelderman | Pres. Diagnostics & Genom | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Nov 2021 | 500 | 2,152 | - | - | Stock Option (Right to Buy) | |
| Bio-Techne Corp | Kim Kelderman | Pres. Diagnostics & Genom | Exercise or conversion of derivative security received from the company (such as an option) at price $ 150.78 per share. | 19 Nov 2021 | 500 | 500 (0%) | 0% | 150.8 | 75,390 | Common Stock |
| Bio-Techne Corp | Kim Kelderman | Pres. Diagnostics & Genom | Sale of securities on an exchange or to another person at price $ 505.78 per share. | 19 Nov 2021 | 400 | 0 (0%) | 0% | 505.8 | 202,313 | Common Stock |
| Bio-Techne Corp | Kim Kelderman | Pres. Diagnostics & Genom | Sale of securities on an exchange or to another person at price $ 503.76 per share. | 19 Nov 2021 | 100 | 400 (0%) | 0% | 503.8 | 50,376 | Common Stock |
| Bio-Techne Corp | Kim Kelderman | Pres. Diagnostics & Genom | Sale of securities on an exchange or to another person at price $ 529.04 per share. | 22 Sep 2021 | 822 | 0 (0%) | 0% | 529.0 | 434,871 | Common Stock |
| Bio-Techne Corp | Kim Kelderman | Pres. Diagnostics & Genom | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2021 | 6,486 | 6,486 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne Corp | Kim Kelderman | Pres. Diagnostics & Genom | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2021 | 4,864 | 4,864 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne Corp | Kim Kelderman | Pres. Diagnostics & Genom | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Aug 2021 | 1,691 | 0 | - | - | Restricted Stock Units | |
| Bio-Techne Corp | Kim Kelderman | Pres. Diagnostics & Genom | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Aug 2021 | 1,691 | 1,691 (0%) | 0% | 0 | Common Stock | |
| Bio-Techne Corp | Kim Kelderman | Pres. Diagnostics & Genom | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2021 | 1,245 | 1,245 | - | - | Restricted Stock Units | |
| Bio-Techne Corp | Kim Kelderman | Pres. Diagnostics & Genom | Payment of exercise price or tax liability using portion of securities received from the company at price $ 481.82 per share. | 06 Aug 2021 | 869 | 822 (0%) | 0% | 481.8 | 418,702 | Common Stock |
| Bio-Techne Corp | Kim Kelderman | Pres. Diagnostics & Genom | Sale of securities on an exchange or to another person at price $ 433.00 per share. | 09 Jun 2021 | 811 | 0 (0%) | 0% | 433 | 351,163 | Common Stock |
| Bio-Techne Corp | Kim Kelderman | Pres. Diagnostics & Genom | Sale of securities on an exchange or to another person at price $ 424.00 per share. | 25 May 2021 | 845 | 811 (0%) | 0% | 424 | 358,280 | Common Stock |
| Bio-Techne Corp | Kim Kelderman | Pres. Diagnostics & Genom | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2021 | 1,667 | 0 | - | - | Restricted Stock Units | |
| Bio-Techne Corp | Kim Kelderman | Pres. Diagnostics & Genom | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2021 | 1,667 | 2,512 (0%) | 0% | - | Common Stock | |
| Bio-Techne Corp | Kim Kelderman | Pres. Diagnostics & Genom | Payment of exercise price or tax liability using portion of securities received from the company at price $ 427.49 per share. | 01 May 2021 | 856 | 1,656 (0%) | 0% | 427.5 | 365,931 | Common Stock |
| Bio-Techne Corp | Kim Kelderman | Pres. Diagnostics & Genom | Sale of securities on an exchange or to another person at price $ 388.45 per share. | 05 Feb 2021 | 823 | 845 (0%) | 0% | 388.4 | 319,694 | Common Stock |
| Bio-Techne Corp | Kim Kelderman | Pres. Diagnostics & Genom | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Aug 2020 | 11,988 | 11,988 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne Corp | Kim Kelderman | Pres. Diagnostics & Genom | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Aug 2020 | 8,991 | 8,991 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne Corp | Kim Kelderman | Pres. Diagnostics & Genom | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Aug 2020 | 8,325 | 8,325 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne Corp | Kim Kelderman | Pres. Diagnostics & Genom | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Aug 2020 | 8,325 | 8,325 | - | - | Stock Options (Right to Buy) | |
| Bio-Techne Corp | Kim Kelderman | Pres. Diagnostics & Genom | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Aug 2020 | 2,015 | 2,015 | - | - | Restricted Stock Units |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges